AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with…
Press Release, November 20, 2023 Connect, Collaborate, Innovate: the PSCC Unveils 'PSCC Connect', the Association of Economic Stakeholders in Oncology…
Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2-…
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market…
LUND, SE / ACCESSWIRE / November 20, 2023 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that…
Revolutionary Medical Device Companies Awarded with Prestigious Mid-Stage Grand Prize and Value Award at the MedTech Strategist Innovation SummitLOS ANGELES--(BUSINESS…
TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…
The 10-year strategic collaboration builds on strong research foundations in medical imaging and expands the scope to advance the delivery…
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or…
Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to…